MedTrace Logo

Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients

NCT01312766 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2016-07-22

Study results available
· View outcomes & findings →

Summary

The purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety of two different subcutaneous hMG preparations when administered to patients undergoing controlled ovarian stimulation for IVF.

Conditions

Interventions

DRUG

Menotropins

Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.

DRUG

Menotropins

Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.

Sponsors & Collaborators

  • IBSA Institut Biochimique SA

    lead INDUSTRY

Principal Investigators

  • Dominique De Ziegler, MD, Prof · Hopital Cochin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-04-30
Completion
2013-12-31

Countries

  • Denmark
  • France
  • Hungary
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01312766 on ClinicalTrials.gov